TITLE

Fibromuscular Hyperplasia of the Brachial Artery--Failure of Calcium Antagonist Therapy

AUTHOR(S)
Olson, Leatrice A.; Faber, D. Bruce; LeMar, Jerold V.; Routman, Burton N.; Hoff, Gary L.
PUB. DATE
December 1984
SOURCE
Angiology;Dec1984, Vol. 35 Issue 12, p790
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Fibromuscular dysplasia (FMD) of the arteries of the extremities has been reported few times in the literature. The clinical significance of FMD relates to the consequences of interruption of arterial blood to the tissues. We report here the second case of FMD of the brachial artery and discuss the failure of the calcium channel blocker, nifedipine, in the therapy of this disorder. A review of the pertinent literature is included.
ACCESSION #
17699671

 

Related Articles

  • Cardene.  // ED Nursing;Sep2009 Supplement, p4 

    The article offers information about the therapeutic functions of Cardene, nicardipine hydrochloride, a calcium channel blocker given IV for hypertensive crisis. It works by blocking the passage of calcium into cardiac and vascular smooth muscle. Its onset us within 5 minutes and peaks at 19...

  • Prescal.  // Royal Society of Medicine: Medicines;2002, p451 

    This article presents information on the prescal which is a proprietary, prescription-only preparation of calcium-channel blocker isradipine. The drug can be used as an antihypertensive. It is available in tablet form.

  • A Treatment Algorithm for Pulmonary Arterial Hypertension. Galiè, Nazzareno // Advances in Pulmonary Hypertension;2014, Vol. 13 Issue 1, p31 

    The treatment algorithm for pulmonary arterial hypertension (PAH) represents graphically a sequence of operations that are needed for the management of patients. The treatment algorithm includes different types of recommendations with varying degrees of scientific evidence. The recommendations...

  • Metabolic Effects of Manidipine. Cavalieri, Luca; Cremonesi, Giovanni // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 3, p163 

    The calcium channel antagonists (CCAs) were originally introduced as vasodilators for the treatment of coronary heart disease, but are now also noted for their clinical efficacy in the management of hypertension. Data from large clinical studies have shown that CCAs are not associated with the...

  • CARDIOVASCULAR SYSTEM.  // Nurse Practitioners Prescribing Reference;Summer2010, Vol. 17 Issue 2, p3 

    The article offers information on various drugs for cardiovascular system diseases. It says that benicar is an angiotensin II receptor blocker from Daiichi Sankyo Co. Ltd. used to prevent hypertension, and is applicable for adults who are 16 years old and above. It says that calan is a calcium...

  • CALCIUM CHANNEL BLOCKERS. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2011, p218 

    The article presents information on calcium channel blockers for use as antiarrhythmic and antianginal agents, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Late Systolic Wave on Brachial Artery Blood Flow Velocity Pattern in Patients with Coronary Artery Disease and Its Relation to Vascular Stiffness. Guler, Niyazi; Eryonucu, Beyhan; Bilge, Mehmet; Etlik, Omer; Erkoc, Reha; Sakarya, Mehmet Emin // Angiology;Aug2001, Vol. 52 Issue 8 

    Describes the late systolic wave on brachial artery blood flow velocity pattern in patients with coronary artery diseases. Link between late systolic wave and vascular stiffness; Chronic changes in arterial circulations; Normal triphasic pattern of brachial artery.

  • Calcium channel blockers ease GI symptoms. Geyerhahn, George; Baker, James M. // Cortlandt Forum;6/25/95, Vol. 8 Issue 6, p8 

    Comments on positive side effects of calcium channel blockers in patients with diarrhea or irritable bowel syndrome (IBS). Constipation as a result in one patient; Relaxation of smooth muscles.

  • Newest calcium antagonist offers added features.  // Drug Topics;7/7/97, Vol. 141 Issue 13, p7 

    States that Posicor (mibefradil), from the category of tetralol calcium antagonist has been approved for the treatment of hypertension and chronic stable angina pectoris. Benefits of the drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics